Melissa Hollo: How HerCare Utilizes Hierarchical Algorithm of Severe Maternal Morbidity
Melissa Hollo, Director of Project Management at hc1 and Licensed Independent Clinical Social Worker, shared a post on LinkedIn:
“A recent study titled ‘Hierarchical algorithm identifies methods of severe maternal morbidity’ by Joshua Fitch, Senior Editor, published in Obstetrics and Gynecology, highlights a significant advancement in our understanding of severe maternal morbidity.
The study emphasizes the need for earlier and more precise identification of risks.
The research introduces a hierarchical algorithm that achieves a 94.5% concordance with manual chart reviews in identifying the primary drivers of maternal morbidity.
Key findings indicate that hemorrhage, hypertension, and infection are major contributors to maternal complications, with hypertension and infection alone responsible for nearly 45% of non-transfusion related cases.
While this study provides clarity on the factors driving maternal morbidity, it also highlights a critical gap in care: risks are often identified only after they have escalated.
At hc1, we are addressing this issue through HerCare.
HerCare utilizes a hierarchical, data-driven approach to identify maternal risk earlier in the care journey, before complications become severe.
By integrating clinical, lab, and longitudinal patient data, we empower providers to proactively detect risks such as iron deficiency, hypertensive disorders, and infections – conditions that significantly contribute to morbidity.
The opportunity lies not just in better classification, but in intervention.
By identifying these risks sooner, we can:
- Improve maternal outcomes and reduce preventable complications
- Decrease costly acute interventions and hospital utilization
- Close the gap between morbidity and mortality drivers through earlier care pathways
We can begin to shift the curve on maternal health by combining clinical insight with actionable intelligence at the point of care.
Learn how we’re supporting earlier maternal risk detection.”
More posts featuring Melissa Hollo on Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026